Considering the increasing emphasis on immunotherapeutic strategies in bladder cancer management, our findings on RHOJ’s potential as a diagnostic biomarker and its association with immune response open new avenues for therapeutic interventions. Here, RHOJ is linked to urinary bladder carcinoma.